P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408)

Bibliographic Details
Main Authors:	S. Loges, M. Heuser, J. Chromik, G. Sutamtewagul, S. Kapp-Schwoerer, M. Crugnola, N. Di Renzo, R. Lemoli, D. Mattei, I. Ben-Batalla, J. Waizenegger, L.-M. Rieckmann, M. Janning, C. D. Imbusch, N. Beumer, D. Micklem, C. Gorcea-Carson, G. Lawson, J. Nautiyal, S. Deharo, W. Fiedler, Y. Alvarado-Valero, B. Gjertsen
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845080.27665.da

Internet